Publications

GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity

 122
GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity

Tags:

Previous Article

Oncogene mutation in colorectal cancer leads to metabolic reprogramming

Next Article

GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity

Related Posts

Oligodendrocyte mechanotransduction channel TMEM63A regulates myelin sheath geometry

Oligodendrocyte mechanotransduction channel TMEM63A reg...

 60

Familial Alzheimer mutations stabilize synaptotoxic g-secretase-substrate complexes

Familial Alzheimer mutations stabilize synaptotoxic g-s...

 102

Pumilio differentially binds to mRNA 3′ UTR isoforms to regulate localization of synaptic proteins

Pumilio differentially binds to mRNA 3′ UTR isoforms to...

 103